Skip to main content
Edward Wolin, MD, Oncology, New York, NY, The Mount Sinai Hospital

EdwardMWolinMD

Oncology New York, NY

Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology

Director of the Center for Carcinoid and Neuroendocrine Tumors, Tisch Cancer Institute at Mount Sinai, Professor of Medicine, Medical Oncology at Icahn School of Medicine at Mount Sinai

Overview of Dr. Wolin

Dr. Wolin is Director of the Center for Carcinoid and Neuroendocrine Tumors
at the Tisch Cancer Institute at Mount Sinai, and Professor of Medicine, Medical
Oncology, at the Icahn School of Medicine at Mount Sinai. The Center for Carcinoid and Neuroendocrine Tumors features robust research program, with clinical trials including immunotherapy, biologic agents, peptide receptor radionuclide therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, MET inhibitors, antiangiogenic drugs, and peptide receptor radiotherapy using both the somatostatin receptor and norepinephrine transporter as molecular targets.
Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor
Program at Montefiore Einstein Cancer Center. Previously, he worked for more than
two decades at Cedars-Sinai Medical Center in Los Angeles, where he founded
and directed the large Carcinoid and Neuroendocrine Tumor Program in that
institution, and subsequently directed the Neuroendocrine Tumor Program at University
of Kentucky. Dr. Wolin is Co-Medical Director for the Carcinoid Cancer Foundation
and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the
American Association for Cancer Research. He has published in many prestigious
journals, including the New England Journal of Medicine and Journal of Clinical
Oncology, and is a reviewer for numerous journals, including Journal of Clinical
Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The
Lancet Oncology.
Dr. Wolin earned his medical degree from Yale School of Medicine. He completed
both his residency in internal medicine and fellowship in medical oncology at
Stanford University Hospital. He was also a clinical fellow at the National Cancer
Institute of the National Institutes of Health. Dr. Wolin is board certified in Internal
Medicine and Medical Oncology.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1979
  • Clinical Center at the National Institutes of Health
    Clinical Center at the National Institutes of HealthFellowship, Clinical Associate , 1977
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1976
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1974 - 1975
  • Yale School of Medicine
    Yale School of MedicineClass of 1974
  • Reed College
    Reed CollegeBA, Biology , 1970

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2009 - Present
  • NJ State Medical License
    NJ State Medical License 2021 - 2025
  • NY State Medical License
    NY State Medical License 2015 - 2024
  • CA State Medical License
    CA State Medical License 1975 - 2022
  • KY State Medical License
    KY State Medical License 2014 - 2016
  • IA State Medical License
    IA State Medical License 2013 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Patient’s Choice Physician Award 2009, 2010. 2011, 2012
  • Excellence Award Healthnetwork Foundation Service, 2009
  • Member Sigma Xi Honorary Scientific Research Society, 1974
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The ghost carcinoid in a patient with 120-fold elevated 5-HIAA.  
    Yu, R., Wolin, E, Endocr Pract, 1:1-6

Books/Book Chapters

Abstracts/Posters

  • Lipovitellin Uptake into the Yolk Spheres Of Developing Crustacean Oocytes.
    Wolin, E.M., Laufer, H, Sixty-eighth Annual Meeting of the American Association for the Advancement of Science, American Zoologist
  • A Randomized Comparison of PAVe as Adjuvant Chemotherapy for Hodgkin’s Disease.
    Wolin, E.M., Rosenberg, S.A., Kaplan, H.S, Adjuvant Therapy of Cancer II: Proceedings of the Second International Conference in the Adjuvant..., Tucson, Arizona
  • Current Stanford Results Utilizing MOP (P) vs. PAVe as Adjuvant Chemotherapy for Hodgkin’s Disease.
    Wolin, E.M., Thompson, J.M., Horning, S.J., Hoppe, R.T., Kaplan, H.S., Rosenberg, S.A, ASCO Annual Meeting, San Diego, CA
  • Join now to see all

Lectures

  • Introduction to Centres of Excellence – Challenges Overcome and Challenges Ahead. 
    Carcinoid NeuroEndocrine Tumour Society Canada, Ottawa, ON, Canada
  • Expert Panel Consensus Statements on the Medical Treatment of Unresectable Pancreatic Neuroendocrine Tumors. 
    94th Annual Meeting of The Endocrine Society - ENDO 2012, The Endocrine Society, Houston, TX
  • Strategies for Management of Secondary Conditions in Carcinoid/NET Patients. 
    NANETS Conference, Southampton, Bermuda
  • Join now to see all

Other

  • In Her Own Time. 
    Wolin, E, Dir. Lynne Littman
  • Steve Jobs Death brings Spotlight to Rare Type of Pancreatic Cancer. 
    Wolin, E, KABC News. ABC
    KABC, Los Angeles
  • Interview with Dr. Wolin about the shark cartilage controversy. 
    Wolin, E, KNBC News. NBC
    KNBC, Los Angeles
  • Join now to see all

Press Mentions

  • The Carcinoid Cancer Foundation and PlatformQ Health to Host Live, Online Education on Carcinoid Syndrome
    The Carcinoid Cancer Foundation and PlatformQ Health to Host Live, Online Education on Carcinoid SyndromeFebruary 23rd, 2017
  • ) Et Le Telotristat éthyle* Lors Du Congrès 2016 De L’European Society for Medical Oncology (ESMO)
    ) Et Le Telotristat éthyle* Lors Du Congrès 2016 De L’European Society for Medical Oncology (ESMO)September 27th, 2016
  • Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (Somatuline
    Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (SomatulineSeptember 27th, 2016

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    BCBS Alabama PPO
    BCBS Blue Card PPO
    BCBS California CaliforniaCare HMO
    BCBS California PPO
    Blue Shield California PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    Great West PPO
    Harvard Pilgrim HMO
    Health Net California Large Group PPO
    Health Net HMO - Employer Group
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment